FEATURED ARTICLES
Precision Medicine Needs Better Infrastructure — And We Already Have The Models For It
Standard methods for evaluating clinical trial representativeness perform poorly when the trial population differs from the broader disease population in a patient registry. June Cha, Ph.D., MPH, explains how the right metrics can make a difference.
-
Clinical Failures Persist Because They're Structural, Not Random
Clinical failures are no longer contained within a single program but happen across portfolios, companies, and therapeutic areas. Advisor Mikail Evteev suggests the reason is a failure to learn from past mistakes.
-
Breaking Barriers In Rare Disease Clinical Trials
Priovant Therapeutics CEO Ben Zimmer shares lessons learned from rare disease VALOR trial exploring a new therapy for the treatment of dermatomyositis.
-
Justice In Human Participant Research: Reinterpreting Belmont For Contemporary Clinical Trials
Experienced IRB professional Stephanie Pyle revisits the Belmont Report to consider what its principle of “justice” means for research studies developed and conducted today.